| Primary |
| Hodgkin's Disease |
36.8% |
| Testis Cancer |
18.8% |
| Non-hodgkin's Lymphoma |
6.7% |
| Malignant Mediastinal Neoplasm |
3.5% |
| Germ Cell Cancer |
2.9% |
| Hodgkin's Disease Stage Iii |
2.9% |
| Penis Carcinoma |
2.4% |
| Testicular Seminoma (Pure) |
2.4% |
| Bone Sarcoma |
2.2% |
| Craniopharyngioma |
2.2% |
| Hodgkin's Disease Stage Iv |
2.2% |
| Lymphoproliferative Disorder |
2.2% |
| Diffuse Large B-cell Lymphoma |
2.0% |
| Ovarian Germ Cell Cancer |
2.0% |
| Product Used For Unknown Indication |
2.0% |
| Seminoma |
2.0% |
| Drug Use For Unknown Indication |
1.8% |
| Lymphoma |
1.8% |
| Malignant Melanoma |
1.8% |
| Ewing's Sarcoma |
1.3% |
|
| Febrile Neutropenia |
8.7% |
| Pneumonitis |
7.7% |
| Pulmonary Toxicity |
7.7% |
| Respiratory Failure |
7.7% |
| Azoospermia |
5.8% |
| Interstitial Lung Disease |
5.8% |
| Pulmonary Embolism |
5.8% |
| Pyrexia |
5.8% |
| Acute Myeloid Leukaemia |
4.8% |
| Neutrophil Count Decreased |
4.8% |
| Pulmonary Fibrosis |
4.8% |
| Thrombocytopenia |
4.8% |
| Osteonecrosis |
3.8% |
| Vomiting |
3.8% |
| White Blood Cell Count Decreased |
3.8% |
| Deep Vein Thrombosis |
2.9% |
| Pulmonary Haemorrhage |
2.9% |
| Renal Vein Thrombosis |
2.9% |
| Shock |
2.9% |
| Subcutaneous Emphysema |
2.9% |
|
| Secondary |
| Hodgkin's Disease |
42.2% |
| Non-hodgkin's Lymphoma |
9.0% |
| T-cell Lymphoma |
6.2% |
| Diffuse Large B-cell Lymphoma |
5.7% |
| Lymphoma |
4.0% |
| Lung Neoplasm Malignant |
3.6% |
| Testis Cancer |
3.5% |
| Breast Cancer |
3.5% |
| B-cell Lymphoma |
2.7% |
| Chronic Lymphocytic Leukaemia |
2.4% |
| Germ Cell Cancer |
2.0% |
| Product Used For Unknown Indication |
1.9% |
| B-cell Small Lymphocytic Lymphoma |
1.8% |
| Hodgkin's Lymphoma |
1.7% |
| Acute Myeloid Leukaemia |
1.7% |
| Testicular Germ Cell Cancer |
1.7% |
| Mantle Cell Lymphoma |
1.7% |
| Acute Lymphocytic Leukaemia |
1.6% |
| Plasma Cell Myeloma |
1.6% |
| Bone Sarcoma |
1.4% |
|
| Neutropenic Infection |
14.8% |
| Osteonecrosis |
9.1% |
| Pulmonary Toxicity |
8.3% |
| Thrombocytopenia |
6.7% |
| Toxicity To Various Agents |
6.7% |
| Myelodysplastic Syndrome |
6.5% |
| Vomiting |
5.6% |
| Pulmonary Fibrosis |
4.8% |
| Acute Myeloid Leukaemia |
4.3% |
| Febrile Neutropenia |
4.3% |
| Tuberculosis |
4.0% |
| Renal Failure Acute |
3.8% |
| White Blood Cell Count Decreased |
3.5% |
| Pneumonia |
3.0% |
| Neutropenic Sepsis |
2.7% |
| Pyrexia |
2.7% |
| Respiratory Failure |
2.4% |
| Traumatic Lung Injury |
2.4% |
| Death |
2.2% |
| Malignant Neoplasm Progression |
2.2% |
|
| Concomitant |
| Hodgkin's Disease |
24.2% |
| Chemotherapy |
10.6% |
| Product Used For Unknown Indication |
8.0% |
| Diffuse Large B-cell Lymphoma |
6.5% |
| Hiv Infection |
6.4% |
| Drug Use For Unknown Indication |
6.3% |
| Anaemia Haemolytic Autoimmune |
5.2% |
| Testis Cancer |
5.0% |
| Non-hodgkin's Lymphoma |
4.8% |
| Chronic Lymphocytic Leukaemia |
4.1% |
| Eczema |
3.7% |
| Lymphoma |
3.3% |
| Angioimmunoblastic T-cell Lymphoma |
2.5% |
| Germ Cell Cancer |
1.7% |
| T-cell Lymphoma Stage Iv |
1.6% |
| Testicular Mass |
1.4% |
| Testicular Cancer Metastatic |
1.3% |
| Kaposi's Sarcoma |
1.2% |
| Nausea |
1.2% |
| T-cell Lymphoma |
1.2% |
|
| Neutropenia |
7.9% |
| Progressive Multifocal Leukoencephalopathy |
6.3% |
| Pulmonary Fibrosis |
6.3% |
| Pyrexia |
6.3% |
| Wound Infection |
6.3% |
| Hodgkin's Disease |
5.5% |
| Pulmonary Toxicity |
5.5% |
| White Blood Cell Count Increased |
5.5% |
| Febrile Neutropenia |
4.7% |
| Rash Papular |
4.7% |
| Sepsis |
4.7% |
| Therapy Non-responder |
4.7% |
| Vomiting |
4.7% |
| Weight Decreased |
4.7% |
| Peripheral Motor Neuropathy |
3.9% |
| Respiratory Disorder |
3.9% |
| Treatment Related Secondary Malignancy |
3.9% |
| White Blood Cell Count Decreased |
3.9% |
| Chronic Lymphocytic Leukaemia |
3.1% |
| Exposure During Pregnancy |
3.1% |
|
| Interacting |
| Hodgkin's Disease |
66.7% |
| Neutropenia |
33.3% |
|
|
